

**SUPPLEMENTARY TABLE 1. Estimated vaccination coverage among children aged 19–35 months, by selected vaccines and doses, race/ethnicity,\* and poverty level† — National Immunization Survey-Child, United States, 2017<sup>§</sup>**

Vaccine/Dose	Race/Ethnicity					Poverty Level			
	White, non-Hispanic (Referent) (n = 8,929) % (95% CI)	Black, non-Hispanic (n = 1,104) % (95% CI)	Hispanic (n = 3,175) % (95% CI)	American Indian/Alaska Native, non-Hispanic (n = 195) % (95% CI)	Asian, non-Hispanic (n = 755) % (95% CI)	Native Hawaiian or other Pacific Islander, non-Hispanic (n = 69) % (95% CI)	Multiple races, non-Hispanic (n = 1,106) % (95% CI)	At or above poverty (Referent) (n = 11,392) % (95% CI)	Below poverty (n = 3,337) % (95% CI)
<b>DTaP<sup>¶</sup></b>									
≥3 doses	93.9 (92.8–94.8)	92.2 (89.6–94.2)	94.7 (92.8–96.1)	89.8 (81.8–94.5)	97.6 (95.9–98.6)**	92.6 (79.0–97.7)	93.7 (90.4–95.9)	94.7 (93.9–95.5)	92.4 (90.5–93.8)**
≥4 doses	83.0 (81.4–84.5)	79.7 (76.0–82.9)	84.7 (81.8–87.1)	74.4 (63.9–82.6)	89.1 (84.5–92.4)**	— <sup>††</sup>	81.7 (76.6–85.8)	85.2 (83.8–86.4)	78.5 (75.7–81.0)**
<b>Polio</b>									
(≥3 doses)	92.3 (91.2–93.3)	91.5 (88.9–93.6)	93.2 (91.0–94.9)	89.7 (81.7–94.4)	96.7 (94.8–97.9)**	91.2 (78.1–96.8)	93.2 (89.9–95.5)	93.3 (92.2–94.2)	91.4 (89.6–93.0)
<b>MMR<sup>§§</sup></b>									
(≥1 dose)	91.2 (90.1–92.2)	89.5 (86.9–91.7)	92.2 (89.7–94.1)	89.5 (82.0–94.1)	95.1 (92.3–96.9)**	— <sup>††</sup>	91.8 (88.8–94.1)	92.7 (91.8–93.5)	88.7 (86.4–90.7)**
<b>Hib</b>									
Primary series <sup>¶¶</sup>	92.9 (91.8–93.8)	91.2 (88.5–93.3)	93.3 (90.8–95.1)	87.9 (79.5–93.1)	95.2 (92.6–96.9)	90.9 (77.8–96.6)	92.2 (88.7–94.7)	93.8 (92.9–94.6)	90.4 (88.1–92.3)**
Full series <sup>¶¶</sup>	81.0 (79.3–82.5)	77.4 (73.6–80.8)	81.0 (77.5–84.0)	77.1 (66.8–84.9)	87.3 (83.3–90.4)**	— <sup>††</sup>	79.3 (73.9–83.9)	83.2 (81.7–84.6)	75.2 (72.2–77.9)**
<b>HepB</b>									
(≥3 doses)	91.1 (90.0–92.1)	91.8 (89.2–93.8)	91.3 (88.6–93.4)	88.1 (78.8–93.6)	94.7 (90.6–97.0)**	90.7 (77.8–96.5)	91.1 (87.5–93.8)	92.1 (91.2–93.0)	89.8 (87.3–91.8)
Birth dose <sup>***</sup>	71.3 (69.5–73.0)	75.6 (69.9–80.6)	76.2 (72.2–79.7)**	83.6 (74.8–89.8)**	76.7 (69.7–82.4)	— <sup>††</sup>	72.2 (65.5–78.0)	73.1 (71.3–74.9)	74.6 (71.1–77.7)
<b>Varicella<sup>§§</sup></b>									
(≥1 dose)	90.3 (89.2–91.4)	89.3 (86.6–91.5)	91.8 (89.2–93.7)	88.1 (80.5–93.1)	95.7 (93.2–97.3)**	— <sup>††</sup>	92.9 (90.2–94.9)	92.0 (91.0–92.8)	88.9 (86.6–90.9)**
<b>PCV</b>									
≥3 doses	92.2 (91.1–93.2)	91.2 (88.5–93.3)	92.0 (89.0–94.2)	85.6 (75.9–91.8)	89.9 (82.9–94.3)	90.9 (77.8–96.6)	93.1 (89.8–95.5)	93.1 (91.9–94.0)	89.5 (87.0–91.6)**
≥4 doses	84.2 (82.6–85.6)	78.1 (74.3–81.5)**	81.8 (78.5–84.7)	72.5 (62.1–81.0)**	82.1 (75.1–87.5)	— <sup>††</sup>	82.3 (77.2–86.4)	85.3 (83.9–86.6)	75.9 (73.0–78.7)**
<b>HepA</b>									
(≥1 dose)	84.3 (82.8–85.7)	85.4 (82.1–88.2)	87.9 (84.9–90.3)**	89.5 (82.0–94.1)	91.1 (83.8–95.3)**	— <sup>††</sup>	86.9 (83.0–90.0)	87.4 (86.2–88.6)	84.0 (81.3–86.3)**
(≥2 doses)	58.3 (56.4–60.1)	54.0 (49.0–58.9)	63.5 (59.8–67.0)**	— <sup>††</sup>	68.9 (61.8–75.2)**	— <sup>††</sup>	59.5 (53.5–65.1)	61.4 (59.6–63.2)	56.0 (52.7–59.2)**
<b>Rotavirus<sup>†††</sup></b>	76.6 (74.9–78.2)	65.7 (60.2–70.8)**	71.1 (67.1–74.8)**	— <sup>††</sup>	73.0 (65.2–79.6)	— <sup>††</sup>	73.4 (67.9–78.3)	77.9 (76.1–79.6)	64.4 (61.1–67.6)**
<b>Combined 7-vaccine series<sup>§§§</sup></b>	71.5 (69.7–73.2)	66.5 (62.0–70.7)**	70.4 (66.8–73.7)	65.9 (55.3–75.1)	72.4 (65.1–78.6)	— <sup>††</sup>	69.8 (64.0–75.0)	73.8 (72.1–75.4)	62.8 (59.6–66.0)**
<b>No vaccinations</b>	1.5 (1.2–1.9)	— <sup>††</sup>	— <sup>††</sup>	— <sup>††</sup>	— <sup>††</sup>	— <sup>††</sup>	— <sup>††</sup>	1.1 (0.9–1.4)	1.0 (0.7–1.4)

**Abbreviations:** CI = confidence interval; DTaP = diphtheria, tetanus toxoids, and acellular pertussis vaccine; HepA = hepatitis A vaccine; HepB = hepatitis B vaccine; Hib = *Haemophilus influenzae* type b conjugate vaccine; MMR = measles, mumps, and rubella vaccine; PCV = pneumococcal conjugate vaccine.

\* Children’s race/ethnicity was reported by parent or guardian. Children identified in this report as white, black, Asian, American Indian/Alaska Native, Native Hawaiian or other Pacific Islander, or multiple races were reported by the parent or guardian as non-Hispanic. Children identified as being of multiple races had more than one race category selected. Children identified as Hispanic might be of any race.

† Children were classified as below the federal poverty line if their total family income was less than the poverty threshold specified for the applicable family size and number of children aged <18 years. Children with total family income at or above the poverty threshold specified for the applicable family size and number of children aged <18 years were classified as at or above the poverty level. A total of 604 children with adequate provider data and missing data on income were excluded from the analysis. Poverty level was based on 2016 U.S. Census poverty thresholds (<https://www.census.gov/data/tables/time-series/demo/income-poverty/historical-poverty-thresholds.html>).

§ Children in the 2017 National Immunization Survey-Child were born January 2014–May 2016.

¶ Includes children who might have been vaccinated with diphtheria and tetanus toxoids vaccine or diphtheria, tetanus toxoids, and pertussis vaccine.

\*\* Statistically significant (p<0.05) difference compared with the referent group.

†† Estimate not available because the 95% CI was ≥20.

§§ Includes children who might have been vaccinated with measles, mumps, rubella, and varicella vaccine.

¶¶ Hib primary series: receipt of ≥2 or ≥3 doses, depending on product type received; full series: primary series and booster dose includes receipt of ≥3 or ≥4 doses, depending on product type received.

\*\*\* One dose HepB administered from birth through age 3 days.

††† Includes ≥2 or ≥3 doses, depending on product type of vaccine received (≥2 doses for Rotarix [RV1], or ≥3 doses for RotaTeq [RV5]).

§§§ The combined 7-vaccine series (4:3:1:3\*:3:1:4) includes ≥4 doses of DTaP, ≥3 doses of poliovirus vaccine, ≥1 dose of measles-containing vaccine, the full series of Hib (≥3 or ≥4 doses, depending on product type of vaccine), ≥3 doses of HepB, ≥1 dose of VAR, and ≥4 doses of PCV.